What is Opus Genetics's EV / sales?

Opus Genetics (IRD) reported EV / sales of 22.1× in Q1 2026.

What does EV / sales mean?

Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.

Opus Genetics IRD EV / sales

EV / sales at other companies

AbbVieABBV

7.5×+1.0×

MeiraGTx Holdings plcMGTX

8.7×-7.2×

4D Molecular TherapeuticsFDMT

4.8×-1,729×

Opko HealthOPK

1.6×-0.1×

Regeneron PharmaceuticalsREGN

5.5×+0.6×

RegenxbioRGNX

5.6×+3.6×

Other financials

Income statement

See full

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

See full

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

See full

Operating cash flow-$12.7M-41.5%

Valuation

See full

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

See full

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

See full

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Calculated from Opus Genetics’s reported figures.

enterprise value/total revenue=22.1×

Based on the most recent quarter.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Opus Genetics's EV / sales?: Opus Genetics (IRD) reported EV / sales of 22.1× in Q1 2026.
What does EV / sales mean?: Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.